; (K) research related to improving and measuring the quality of life for individuals with CCM and their families; (L) contributions of genetic variation to clinical presentation as precision medicine targets for therapy; (M) clinical training programs aimed at increasing the number of scientists and clinicians who are trained to treat patients and carry out the research described in this paragraph; (N) proteomic, pharmacological, and cell biological analysis of CCM molecules; (O) biological mechanisms for lesion genesis, development, and maturation; (P) biological mechanisms for lesion bleeding and symptomology; (Q) novel biomedical and pharmacological interventions designed to inhibit new lesion development, lesion growth, and lesion bleeding; and (R) continued research related to understanding better the natural history and clinical variation associated with CCM, particularly as it relates to the development of drug development tools and clinical outcome assessments. (2) Facilitation of research resources